Abstract
Age is a major risk factor for severe outcome of coronavirus disease 2019 (COVID-19), but it remains unclear if this is rather due to increased chronological age or biological age. During lifetime, specific DNA methylation changes are acquired in our genome that act as “epigenetic clocks” allowing to estimate donor age and to provide a surrogate marker for biological age. In this study, we followed the hypothesis that particularly patients with accelerated epigenetic age are affected by severe outcomes of COVID-19. Using four different age predictors, we did not observe accelerated age in global DNA methylation profiles of blood samples of nine COVID-19 patients. Alternatively, we used targeted bisulfite amplicon sequencing of three age-associated genomic regions to estimate donor-age of blood samples of 95 controls and seventeen COVID-19 patients. The predictions correlated well with chronological age, while COVID-19 patients even tended to be predicted younger than expected. Furthermore, lymphocytes in nineteen COVID-19 patients did not reveal significantly accelerated telomere attrition. Our results demonstrate that these biomarkers of biological age are therefore not suitable to predict a higher risk for severe COVID-19 infection in elderly patients.
Competing Interest Statement
WW is cofounder of Cygenia GmbH (www.cygenia.com), which can provide service for epigenetic analysis to other scientists. JF contributes to this company, too. All other authors do not have a conflict of interest to declare.
Clinical Trial
NA
Funding Statement
This work was particularly supported by the German Research Foundation (to WW: WA 1706/8 1 and WA 1706/12-1 within the CRU344; to NM: TRR 219; Project-ID 322900939 [M03, M05]); the Interdisciplinary Center for Clinical Research within the faculty of Medicine at the RWTH Aachen University (WW: O3-3), Deutsche Krebshilfe (WW: TRACK-AML); and the Federal Ministry of Education and Research (WW: VIP + Epi-Blood-Count). The COVA (COVID-19-Aachen) Study was initiated and financed by the University Hospital Aachen.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Blood samples of COVID-19 patients were taken at University Hospital of RWTH Aachen. All patient samples were taken after written and informed consent according to the guidelines and specific approval of the study by the local ethics committee (Ethic approval number EK 080/20 for the Covid-19 Aachen study named COVAS; Ethics committee of RWTH Aachen University, University Hospital Aachen, Pauwelsstrasse 30, 52074 Aachen, Germany) and collected into RWTH cBMB, the central biobank of the medical faculty of RWTH Aachen University (Ethic approval number EK 206/09). Blood samples of healthy donors were taken after written and informed consent according to the guidelines and approval of the study by the local ethics committee (EK 041/15; Ethics committee of RWTH Aachen University, University Hospital Aachen, Pauwelsstrasse 30, 52074 Aachen, Germany).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All raw data will be provided upon reasonable request.
